Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Modus Therapeutics Holding AB (publ)
  6. News
  7. Summary
    MODTX   SE0015987904

MODUS THERAPEUTICS HOLDING AB (PUBL)

(MODTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Modus Therapeutics : engages Lago Kapital as a liquidity guarantor

10/21/2021 | 10:31am EST

STOCKHOLM, SWEDEN - 21 October 2021: Modus Therapeutics Holding AB ("Modus Therapeutics") announces that it has engaged Lago Kapital as a liquidity guarantor for the company's share. The liquidity guarantee starts to run from 22 October 2021.

In its assignment as liquidity guarantor, Lago Kapital will ensure the opportunity to trade in the company's shares by continuously placing trading items on each buy and sell page in the order book. This is in accordance with Nasdaq First North Growth Market regulations regarding liquidity guarantee and means that the liquidity guarantor quotas the purchase and sale volume corresponding to at least SEK 15,000 with a spread of a maximum of 4% between the buy and sell price. The purpose of the liquidity guarantee is to improve the liquidity of the share and reduce the difference between the bid and ask price during ongoing trading.

For this purpose, Karolinska Development lends 40,000 MODTX shares to Lago Kapital pro bono.

For more information on Modus Therapeutics, please contact:

John Öhd, VD, Modus Therapeutics

Telefon: +46 (0) 70 766 80 97

E-post: john.ohd@modustx.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se

About Modus Therapeutics and sevuparin

Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market ("MODTX"). More information is available at www.modustx.com

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects.  Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested - an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

https://news.cision.com/modus-therapeutics/r/modus-therapeutics-engages-lago-kapital-as-a-liquidity-guarantor,c3437764

https://mb.cision.com/Main/20380/3437764/1484378.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about MODUS THERAPEUTICS HOLDING AB (PUBL)
01/14Modus Therapeutics sums up the significant progress on key milestones during 2021, incl..
AQ
2021Modus Therapeutics participates in Aktier Live Sessions
AQ
2021MRKT BUZZ MODUS : Executing on an ambitious timeline
AQ
2021Modus Therapeutics comments on the start of the first clinical study in the planned sep..
AQ
2021First sevuparin dose administered in Modus Therapeutics' Phase 1b LPS provocation study
AQ
2021Modus Therapeutics Holding AB announces first clinical trial participant dose with sevu..
CI
2021Modus Therapeutics publishes interim report for the third quarter 2021
AQ
2021Modus Therapeutics Holding AB Receives Approval to Initiate Clinical Phase 1B Trial wit..
CI
2021Modus Therapeutics Receives Regulatory Approval to Start a Phase 1b Clinical LPS Challe..
AQ
2021MRKT BUZZ MODUS : Benefiting from sepsis care initiative
AQ
More news
Financials
Sales 2021 - - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 55,3 M 5,97 M 5,91 M
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 2
Free-Float -
Chart MODUS THERAPEUTICS HOLDING AB (PUBL)
Duration : Period :
Modus Therapeutics Holding AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 3,44 SEK
Average target price 18,10 SEK
Spread / Average Target 427%
Managers and Directors
John Íhd Chief Executive Officer
Claes Lindblad Chief Financial Officer
Viktor Drvota Chairman
Torsten RŘdiger Goesch Independent Director
Ellen K. Donnelly Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MODUS THERAPEUTICS HOLDING AB (PUBL)-9.61%6
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592
ICON PUBLIC LIMITED COMPANY-18.28%20 601